Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 21, 2026

Aug 21, 2026

•

2 min read

Biotech & Pharma Updates | August 21, 2026

🧬Roche invests $750M to double Oregon Genentech facility, adding fill-finish manufacturing capacity by 2031, Werewolf Therapeutics, Ambros Therapeutics merge in $150M deal targeting rare CRPS-1 pain disorder, Aurinia Pharmaceuticals settles with Teva Pharmaceuticals, protecting Lupkynis from generics until December 2036

Christian Cuchapin, +1

Biotech & Pharma Updates | August 20, 2026

Aug 20, 2026

•

3 min read

Biotech & Pharma Updates | August 20, 2026

🧬 Ultragenyx wins first gene therapy FDA approval for Genglycos (DTX401) targeting glycogen storage disease type Ia via Ph3, Kynexis raises €97M ($113M) Series A, advancing cognitive impairment schizophrenia drug to registrational development, Regeneron wins FDA approval for Pasatru (garetosmab) targeting Activin A in fibrodysplasia ossificans progressiva based on Ph3 data

Christian Cuchapin, +1

Aug 19, 2026

•

3 min read

Biotech & Pharma Updates | August 19

🧬 Merck & Co., Moderna's intismeran autogene (mRNA-4157) plus Keytruda (pembrolizumab) reduces recurrence risk in Ph3 melanoma trial, Trump nominates White House aide Heidi Overton as new FDA commissioner, CSL shares surge 17% on immunoglobulin demand recovery and stronger-than-expected $15.8B revenue

Christian Cuchapin, +1

Biotech & Pharma Updates | August 18, 2026

Aug 18, 2026

•

3 min read

Biotech & Pharma Updates | August 18, 2026

🧬 Amylyx Pharmaceuticals eyes FDA filing for (avexitide) after Ph3 win in post-bariatric hypoglycemia, BioMarin Pharmaceutical acquires Alesta Therapeutics for $275M to challenge AstraZeneca in rare bone disease market, Biokin Pharma's (iza-bren) EGFRxHER3 bispecific ADC meets Ph3 primary endpoint in EGFR-mutated nonsquamous non-small cell lung cancer

Christian Cuchapin, +1

Biotech & Pharma Updates | August 17, 2026

Aug 17, 2026

•

3 min read

Biotech & Pharma Updates | August 17, 2026

🧬 Vera Therapeutics' Trutakna shows kidney function stabilization in Ph3, rivaling Otsuka's Voyxact in immunoglobulin A nephropathy, Slate Medicines reverse merges with Fulcrum Therapeutics, raises $245M for migraine antibody trials on Nasdaq, AstraZeneca's Tagrisso (osimertinib) plus Orpathys (savolitinib) meets PFS and overall survival goals in Ph3 EGFR-mutated non-small-cell lung cancer trial

Christian Cuchapin, +1

Biotech & Pharma Updates | August 14, 2026

Aug 14, 2026

•

3 min read

Biotech & Pharma Updates | August 14, 2026

🧬 FDA grants Bristol Myers Squibb accelerated approval for Zenbexus (iberdomide), a CELMoD agent, for multiple myeloma, Vogenx raises $81.3M IPO, clinical-stage biopharma targeting metabolic serious diseases, Capricor Therapeutics soars after FDA greenlights amendment to DMD cell therapy approval application

Christian Cuchapin, +1

Biotech & Pharma Updates | August 13, 2026

Aug 13, 2026

•

3 min read

Biotech & Pharma Updates | August 13, 2026

🧬 PTC Therapeutics acquires Sangamo Therapeutics' Fabry gene therapy for $111M upfront, $100M milestones, Taiho Pharmaceutical, Cullinan Therapeutics' (zipalertinib) EGFR inhibitor meets Ph3 primary endpoint in first-line non-small cell lung cancer, Akeso's ivonescimab wins China Ph3-backed approval for first-line squamous non-small-cell lung cancer

Christian Cuchapin, +1

Biotech & Pharma Updates | August 12, 2026

Aug 12, 2026

•

3 min read

Biotech & Pharma Updates | August 12, 2026

🧬 BridgeBio's Attruby hits $222M quarterly sales, nearing blockbuster status as ATTR stabilizer-first market emerges, Definium Therapeutics' DT120 (LSD) succeeds in Ph3 trial for generalized anxiety disorder, InduPro raises $77M Series B, backed by Sanofi and Lilly, funding cancer pipeline advancement

Christian Cuchapin, +1

Biotech & Pharma Updates | August 11, 2026

Aug 11, 2026

•

3 min read

Biotech & Pharma Updates | August 11, 2026

🧬 Bristol Myers Squibb commits $2.3B to build Houston manufacturing campus, creating 2,500 jobs, Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.3B, expanding rare epilepsy pipeline, Vaderis Therapeutics raises $152M Series B to advance AKT-targeting HHT treatment

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 21, 2026

Biotech & Pharma Updates | August 20, 2026

Biotech & Pharma Updates | August 19

Biotech & Pharma Updates | August 18, 2026

Biotech & Pharma Updates | August 17, 2026

Biotech & Pharma Updates | August 14, 2026

Biotech & Pharma Updates | August 13, 2026

Biotech & Pharma Updates | August 12, 2026

Biotech & Pharma Updates | August 11, 2026

TLDR Biotech

FAQ

Media Partners